Raimond takes helm at Nuclera

pharmafile | October 26, 2026 | Appointment | |ย ย Biotechnology, Diagnostics, appointmentsย 

Nuclera, the biotechnology company enabling access to innovative protein technologies, has appointed Carl Raimond as Chief Executive Officer, effective immediately. Dr Michael Chen, the companyโ€™s co-founder and former CEO, becomes Chief Scientific and Business Officer, โ€œcontinuing to provide scientific leadership while supporting market development and strategic partnershipsโ€.

The firm said the leadership transition was the next phase in its evolution as it builds on more than a decade of expertise in cell-free protein synthesis, digital microfluidics and protein production, combining โ€œCarlโ€™s experience scaling life-science businesses with Michaelโ€™s scientific leadership and deep understanding of Nucleraโ€™s technology and marketsโ€.

Pic: Martin Lopez

Related Content

Ofichem acquires US drug substance CDMO Kinentia

Ofichem has agreed to acquire Kinentia Biosciences, a US drug substance contract development and manufacturing …

bit.bio expands human heart cell portfolio through myriamed partnership

bit.bio has partnered with German biotechnology company myriamed to offer cryopreserved human induced pluripotent stem …

Could targeting the molecular causes of infertility finally transform IVF success rates?

By Dr Jordan Abdi Over the past two decades, demand for IVF has risen sharply …

The Gateway to Local Adoption Series

Latest content